Write a brochure

NR293 Pharmacology for Nursing Practice

Medication Teaching Plan Guidelines

NR293_RUA_Medication_Teaching_Plan_Guidelines_V3.docx 1

The purpose of this assignment is for the student to synthesize pharmacological knowledge (i.e., core drug
knowledge, core patient variables, and nursing implications) of pharmacotherapeutic agents into a useful
teaching and learning tool for nurses and patients.

Course outcomes: This assignment enables the student to meet the following course outcomes:

CO1 Apply the concepts of pharmacotherapeutics, pharmacokinetics, pharmacodynamics, and pharmacogenomics to

the use of specific medication classifications in specific health conditions and in consideration of medication

side/adverse effects, nursing implications, and medication teaching. (POs 1, 2, and 3)

CO2 Apply principles of health promotion, as well as illness and injury prevention, to promote safety and effectiveness

of commonly used pharmacologic therapy across the lifespan, taking into consideration sociocultural,

genetic/genomic, developmental, and gender implications. (POs 3 and 8)

CO3 Utilize the nursing process in understanding the effects of drug therapy on health outcomes across the lifespan

within the framework of a diverse population of individuals, families, and communities. (PO 4)

Due date: Your faculty member will inform you when this assignment is due . The Late Assignment Policy applies
to this assignment.

Total points possible: 100 points

Preparing the assignment

Follow these guidelines when completing this assignment. Speak with your faculty member if you have questions.
1. Choose a pharmacological agent that has been on the market less than 5 years.

2. Research the literature and obtain two to three resources for current, evidence-based information related to the
pharmacological agent.

3. Develop a teaching brochure and one page paper following these guidelines.
a. Brochure

• Key/Relevant Drug Information (30 points/30%)
o Drug Class
o Mechanism of Action
o Drug Administration and Dosage
o Drug Interactions
o Lab effects/interference
o Special Considerations
o Potential Side Effects/Adverse Effects/Toxicities

• Patient Education Considerations (35 points/35%)
o Nursing Management
o Patient Education Considerations
o Patient Assessment
o Side Effects/Adverse Effects/Toxicities
o Special considerations

• Visual Effects/Creativity (10 points/10%)
o Developed per the required standard
o Appropriate for the intended audience
o Flesch-Kincaid reading level seventh grade or lower
o Graphics enhance the purpose of the brochure
o Brochure is visually appealing

NR293 Pharmacology for Nursing Practice

Medication Teaching Plan Guidelines



Pharmacology Brochure Discussion

Elizabeh Jusu

Chamberlin University College of Nursing


Lisa South

9th December, 2021

Pharmacology Brochure Discussion

This brochure introduces a recent medication that was approved by the FDA but has not been in the market for long. It is a source of quick information but covers most of the essential areas of information that a nurse would need to have on their fingertips concerning the drug. Dayvigo is a sleeping pill that was approved in 2019, and whose effectiveness is quite high (FDA 2020). The drug is a lemborexant of the sedative-hypnotics class. It is an oral tablet whose dosage should not exceed 10mg. When co-administered with a CYP3A inhibitor, the dosage should be kept at only 5mg (Drugs.com, 2021). It is an effective medication for treating insomnia but can have serious side effects so it is essential for nurses to be well aware of its use, contraindications, side effects and other potential issues that could arise from its use.

The role of this brochure was to educate nurses on the existence and use of Dayvigo, an insomnia treatment medication that was recently introduced into the market. The brochure ought to offer all the critical information that nurses and pharmacists need to grasp promptly to effectively use the drug and achieve its full potential as an anti-insomnia medication. It is designed to offer detailed, verifiable and essential information on the drug to nurses and other users quickly and efficiently. It is not meant to be the definite primary education material on the drug, but a quick source of refreshing information on the drug. The brochure will be printed in an easily legible font and has a lot of information on most of the topics which a nurse would typically need to gather before issuing or when matching a patient to a prescription.


Drugs.com. (2021). Lemborexant. Day ago. Full Drug Information. https://www.drugs.com/mtm/lemborexant.html

Food and Drgug Administration (2020). Drug Approval Package- Dayvigo. https://www.google.com/search?q=DAyvigo+FDa&oq=DAyvigo+FDa&aqs=chrome..69i57j35i39l2j0i512l4j69i60.3636j1j7&sourceid=chrome&ie=UTF-8

Drug Interactions

Dayvigo should not be taken with a strong or moderate CYP3A inducers as they could reduce its effectiveness. These include rifampin, carbamazepine, efavirenz, and etravirine.

Special Considerations

Special consideration should be given to patients with complex sleep behaviors such as sleep walking, patients with a compromised respiratory system, chronic depression, suicidal ideation, pregnancy, drug addiction and comorbid diagnosis

Potential Side Effects/Toxicities

Unusual drowsiness, generalized weakness and fatigue, sleep paralysis, somnambulism, allergic reactions, worsening depression or suicidal ideations.


Nursing Indications

he nurse should ensure that the patient is well educated on the drug use, especially the dosage and the potential side effects.

The Nurse should also ensure patient safety by examining occupation,, sleep history and mental health of the patient fist.

Patient Assessment

The patient’s sleep disorder should be assessed as this drug can cause complex sleep disorders. The patient should also not be an operator of heavy machinery as the drug can cause drowsiness at work. The patient should not have a history of sleep paralysis of sleep walking as the drug can make them worse.

Special considerations.

Women who are pregnant should be given special consideration. The drug should not be prescribed to children. Drug addicts and people with liver impairment should be given special consideration too.

Side Effect management

The medication should be changed if serious side effects are experienced.

Regular users should undergo regular liver function tests to determine if it is being affected.

Patients who experience of exhibit signs of depression should cease using the drug.

The dosage should be at the minimum affective level to avoid overdose toxicity.

The medication should only be taken immediately before getting into bed.

The dosage and schedule given by the doctor in the prescription should always be strictly followed.

Patient Education

Patient should not be an addict and should not take alcohol.

Any episodes of sleep paralysis, muscle weakness or sleep activity should be reported promptly.

The patient can experience daytime sleepiness when using the drug, so caution should be taken to avoid causing accidents

Usage of he medication should be ceased immediately if once s the patient is pregnant.

Drug Description

Dayvigo is a lemborexant of the sedative-hypnotics class. It is an oral tablet whose dosage should not exceed 10mg

It can be co-administered with a CYP3A inhibitor

Dayvigo treats insomnia by blocking the binding sites of the wake promoting neuropeptides Orexin A and Orexin B, thereby suppressing wake drive causing drowsiness.